Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
InoviqASX:IIQ -2.78%10 3-Year EPS without NRI Growth Rate is 5.70% as of Dec. 2025, which is 84% above its 10-year median of 3.10. GuruFocus rates ASX:IIQ with a GF Score™ of 10/100 and a GF Value™ of A$0.53 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 160 Medical Diagnostics & Research companies, Inoviq ranks worse than 55% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 5.70% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 1.90% per year.
During the past 10 years, the average EPS without NRI Growth Rate was 15.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Inoviq was 52.20% per year. The lowest was -89.50% per year. And the median was 3.10% per year.
Inoviq (ASX:IIQ) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Inoviq 3-Year EPS without NRI Growth Rate Related Terms
ASX:IIQ vs TMO, DHR, NTRA: 3-Year EPS without NRI Growth Rate Comparison
For the Diagnostics & Research subindustry, Inoviq's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Inoviq 3-Year EPS without NRI Growth Rate vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Inoviq's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Inoviq's 3-Year EPS without NRI Growth Rate falls into.
Inoviq 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 5.70% mean?
Inoviq (ASX:IIQ) has a 3-Year EPS without NRI Growth Rate of 5.70% as of Dec. 2025. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Inoviq and its competitors. This is 84% above median its historical median of 3.10. According to the industry distribution chart, Inoviq ranks #88 out of 160 companies in the Medical Diagnostics & Research industry, placing it in the top 55%.
Is Inoviq's 3-Year EPS without NRI Growth Rate too high?
Inoviq's current 3-Year EPS without NRI Growth Rate of 5.70% is 84% above median its 10-year median of 3.10. The Medical Diagnostics & Research industry median 3-Year EPS without NRI Growth Rate is 11.10. Inoviq's value of 5.70% is 48.6% below this industry median. Based on the distribution chart, Inoviq ranks #88 out of 160 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Inoviq has a GF Score™ of 10/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Inoviq's 3-Year EPS without NRI Growth Rate compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Inoviq ranks #88 out of 160 companies for 3-Year EPS without NRI Growth Rate. This places Inoviq in the lower half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 11.10. Inoviq's value of 5.70% is 48.6% below this benchmark. While the company's 10-year median is 3.10 vs. the industry median of 11.10, Inoviq has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Medical Diagnostics & Research company?
The median 3-Year EPS without NRI Growth Rate among Medical Diagnostics & Research companies is 11.10, based on 160 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Inoviq's current 3-Year EPS without NRI Growth Rate of 5.70% is 48.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Inoviq and its competitors. For the Medical Diagnostics & Research industry, the median 3-Year EPS without NRI Growth Rate is 11.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Inoviq's current 3-Year EPS without NRI Growth Rate is 5.70%, which is 84% above median its own 10-year median of 3.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inoviq stock overvalued right now?
Based on GuruFocus' analysis, Inoviq (ASX:IIQ) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.53, compared to a current price of A$0.18 — trading 67% below its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 5.70%, which is 84% above median its 10-year median of 3.10 and 48.6% below the Medical Diagnostics & Research industry median of 11.10. Inoviq's overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Inoviq (ASX:IIQ), the current 3-Year EPS without NRI Growth Rate is 5.70% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Inoviq (ASX:IIQ) Overvalued in 2026?
Based on GuruFocus' analysis, Inoviq stock appears to be undervalued.
The current stock price of A$0.18 is trading 67% below its estimated GF Value™ of A$0.53.
GuruFocus considers Inoviq to be Possible Value Trap.
Key valuation signals for ASX:IIQ:
3-Year EPS without NRI Growth Rate: 5.70% (84% above median its 10-year median of 3.10)
GF Value™: A$0.53 vs. price of A$0.18 (67% below fair value)
Industry Position: 48.6% below the Medical Diagnostics & Research median (#88 of 160)
No single metric tells the full story. See the ASX:IIQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Inoviq Ltd is engaged in developing and commercializing a portfolio of diagnostic and exosome-based products to improve the diagnosis and treatment of cancer and other diseases. The company has commercialized the hTERT test used as an adjunct to urine cytology testing for bladder cancer and the EXO-NET pan-exosome capture tool for research purposes. Its cancer diagnostic pipeline includes blood tests in development for earlier detection and monitoring of ovarian, breast, prostate, and other cancers. The Group operates predominantly in one business segment, the research and development of cancer diagnostics, and two geographical segments, Victoria, Australia, and the United States of America, with the majority of revenue coming from Australia.
10GF Score
Get the complete analysis for ASX:IIQ
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:IIQ has been successfully added to your 
